| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Net Income | -1.87 | -0.40 |
| Diluted EPS | -0.12 | -0.02 |
- Net Income YoY
- -367.6%
Key highlights
- Net loss widened to $1.87 million in Q3-26 from $0.40 million in Q3-25
- Diluted earnings per share decreased to -$0.12 compared to -$0.02 in the prior year period
- Net income growth declined 367.6% year-over-year
- Company reported a significant working capital deficit of $5,980,129
- Nine-month net loss reached $2,608,351 due to a $1.5 million R&D expense
How the Period Went
Accustem Sciences Inc. experienced a notable downturn in its bottom-line performance during the third quarter of 2026. The company reported a net loss of $1.87 million, representing a 367.6% year-over-year decrease from the $0.40 million loss recorded in the same period of 2025. This widening deficit translated to a diluted earnings per share of -$0.12, down from -$0.02 in the prior year quarter. The results reflect the intensive capital requirements of its current developmental stage, where clinical costs and research initiatives outweighed any revenue generation, leading to a sharp increase in the company's quarterly burn rate.
Margins and Profitability
- Profitability was severely impacted by a $1.5 million expense related to acquired in-process research and development
- The nine-month net loss climbed to $2,608,351, more than doubling the $1,241,708 loss from the previous year
- Operating margins remain under pressure as the company has yet to transition from clinical development to commercial revenue
- Management identified a working capital deficit of nearly $6 million, necessitating continued external funding
- The company continues to rely on related party financing to sustain its clinical-stage diagnostic operations
Business Overview
Accustem Sciences Inc. operates as a biotechnology firm focused on the healthcare sector, specializing in the development and commercialization of advanced diagnostic tests. Its core mission involves leveraging genomic technology to improve patient outcomes through more accurate disease characterization, primarily targeting oncological applications. As a clinical-stage entity, Accustem is currently navigating the complex regulatory and testing phases required to bring proprietary diagnostic tools to the medical market. The company remains focused on high-need segments within the biotechnology landscape where precision medicine can address significant diagnostic gaps.
Financial Context
The current financial results arrive amid a challenging period for Accustem’s market valuation. With a market capitalization of approximately $1.9 million, the company is positioned as a micro-cap player in the biotechnology industry. The stock has faced significant downward pressure, recording a quarter-over-quarter price decline of 50.83% and a monthly drop of 19.97%. The Relative Strength Index of 36.3 suggests the stock is moving toward oversold territory. This volatility is characteristic of clinical-stage biotech firms that rely heavily on related party financing and periodic capital injections to bridge the gap toward commercial viability.
Down 20.0% over the last month ($0.15 on 20 Oct → $0.12 on 19 Nov). Daily closing prices. Source: Yahoo Finance.
Show the prices
| 20 Oct | $0.15 |
|---|---|
| 21 Oct | $0.15 |
| 22 Oct | $0.13 |
| 23 Oct | $0.13 |
| 26 Oct | $0.15 |
| 27 Oct | $0.15 |
| 28 Oct | $0.15 |
| 29 Oct | $0.13 |
| 30 Oct | $0.13 |
| 2 Nov | $0.13 |
| 3 Nov | $0.14 |
| 4 Nov | $0.13 |
| 5 Nov | $0.13 |
| 6 Nov | $0.13 |
| 9 Nov | $0.13 |
| 10 Nov | $0.13 |
| 11 Nov | $0.14 |
| 12 Nov | $0.13 |
| 13 Nov | $0.12 |
| 16 Nov | $0.12 |
| 17 Nov | $0.12 |
| 18 Nov | $0.12 |
| 19 Nov | $0.12 |
| Share price | $0.12 |
|---|---|
| Market cap | $2M |
| 1-month price change | -19.97% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Accustem Sciences Inc. announcing its third quarter 2026 financial results.
Track Accustem Sciences Inc. live
Get the next Accustem Sciences Inc. SEC filing seconds after it lands.



